The global DNA methylation sequencing market is estimated to reach CAGR of 13% during the forecast period (2022-2029).
DNA methylation is a heritable epigenetic marker that involves DNA methyltransferases covalently transferring a methyl group to the C-5 position of the cytosine ring of DNA (DNMTs). In humans, cytosines are primarily methylated in any context of the genome. More than 98 per cent of DNA methylation occurs in somatic cells in a CpG dinucleotide context.
The existing DNA methylation market is favoured by several factors, including a global increase in cancer prevalence, declining sequencing costs, and increasing sequencing output. Furthermore, an increasing number of product approvals and launches in the global DNA methylation market will provide a lucrative growth opportunity for this market. Furthermore, the market is being driven by an increase in early-stage biomarkers in cancer profiling.
An increase in the prevalence of cancer in the market will drive the market growth
Oncology is one of the disciplines where DNA methylation technology is widely employed to develop therapeutic options for rectifying the cancer epigenome’s transcriptional aberrations. Changes in gene function or expression and cellular transformation lead to cancer when epigenetic alterations, such as DNA methylation and histone modification, are disrupted. The importance of DNA methylation technology in oncology may be seen in developing inhibitors of DNA methyltransferases and histone deacetylases (HDACs), which have been proven to be clinically effective in cancer treatment. According to the World Health Organization, approximately 1.8 million new cancer cases were diagnosed worldwide in 2018. According to the WHO, nearly 70% of cancer deaths occur in low- and middle-income countries. Only one in five low- and middle-income countries has the data needed to drive cancer-related policies. This global and widespread threat of cancer remains a major motivator for developing new cancer therapies that aid in risk assessment, early diagnosis, and effective treatment monitoring.
Government funding is also one of the main growth factors for the DNA methylation market. Increased government funding will help research institutes and key players develop and market novel assays useful for diagnosing various tumors. As funding increases, the cancer profiling market will become more liquid, and companies will develop new testing methods to identify the underlying mutations that may cause the disease. As a result, all of these factors are expected to contribute to market growth during the forecast period. This contributes to the growth of the global DNA methylation sequencing market.
Download Sample Brochure @ https://www.datamintelligence.com/download-sample/dna-methylation-sequencing-market
- Polymerase Chain Reaction
The DNA methylation sequencing market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abcam plc,Active Motif Inc, Agilent Technologies Inc, Bio-Rad Laboratories Inc,Diagenode Diagnostics SA, EpiGentek Group Inc,Exact Sciences Corporation, F.Hoffmann-La Roche Ltd,Illumina Inc, Merck KGaA, New England Biolabs Inc, Pacific Biosciences of California Inc, Perkin Elmer Inc, QIAGEN N.V., Thermo Fisher Scientific Inc, Zymo Research Research Corporation.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the DNA methylation sequencing market globally. For instance,
In April 2019, New England Biolabs has released a new product called ‘NEBNext Enzymatic Methyl-seq (EM-seqTM)’ as a methylation analysis alternative to bisulfite sequencing.
DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision-making in designing disruptive solutions.